Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADGlobeNewsWire • 03/08/25
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADGlobeNewsWire • 03/08/25
Investors who Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) should contact Levi & Korsinsky about pending Class Action - REGNAccesswire • 03/07/25
REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud LawsuitPRNewsWire • 03/07/25
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGNAccesswire • 03/07/25
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 – REGNGlobeNewsWire • 03/07/25
Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitBusiness Wire • 03/07/25
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNGlobeNewsWire • 03/07/25
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. – REGNAccesswire • 03/07/25
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!Accesswire • 03/07/25
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron PharmaceuticalsZacks Investment Research • 03/07/25
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)Accesswire • 03/06/25
REGN DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGNAccesswire • 03/06/25
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – REGNAccesswire • 03/06/25
Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens BermanGlobeNewsWire • 03/06/25
Investors in Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGNAccesswire • 03/06/25
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreGlobeNewsWire • 03/06/25
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitPRNewsWire • 03/06/25
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyAccesswire • 03/06/25
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 03/06/25
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNPRNewsWire • 03/06/25
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens BermanAccesswire • 03/06/25
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAccesswire • 03/06/25
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNAccesswire • 03/05/25